ATE229029T1 - 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate - Google Patents

2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate

Info

Publication number
ATE229029T1
ATE229029T1 AT97905824T AT97905824T ATE229029T1 AT E229029 T1 ATE229029 T1 AT E229029T1 AT 97905824 T AT97905824 T AT 97905824T AT 97905824 T AT97905824 T AT 97905824T AT E229029 T1 ATE229029 T1 AT E229029T1
Authority
AT
Austria
Prior art keywords
erythromycin
etheroxime
protected
derivatives
dimethylamine
Prior art date
Application number
AT97905824T
Other languages
English (en)
Inventor
Chengxi Yang
Hemantkumar H Patel
Yi-Kin Ku
Jih-Hua Liu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE229029T1 publication Critical patent/ATE229029T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97905824T 1996-04-02 1997-02-06 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate ATE229029T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/627,795 US5719272A (en) 1996-04-02 1996-04-02 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
PCT/US1997/001952 WO1997036912A1 (en) 1996-04-02 1997-02-06 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin a derivatives

Publications (1)

Publication Number Publication Date
ATE229029T1 true ATE229029T1 (de) 2002-12-15

Family

ID=24516163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905824T ATE229029T1 (de) 1996-04-02 1997-02-06 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate

Country Status (9)

Country Link
US (1) US5719272A (de)
EP (1) EP0891370B1 (de)
JP (1) JP4116674B2 (de)
AT (1) ATE229029T1 (de)
DE (1) DE69717613T2 (de)
DK (1) DK0891370T3 (de)
ES (1) ES2188896T3 (de)
PT (1) PT891370E (de)
WO (1) WO1997036912A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
PT915899E (pt) 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
AP1060A (en) * 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
AR023264A1 (es) * 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
EE200100613A (et) 1999-05-24 2003-02-17 Pfizer Products Inc. 13-metüülerütromütsiini derivaadid
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
GB9915745D0 (en) * 1999-07-06 1999-09-08 Biochemie Sa Organic compounds
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
CA2397092A1 (en) 2000-01-11 2001-07-19 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
ES2243798T3 (es) * 2001-11-07 2005-12-01 Aventis Pharma Deutschland Gmbh Procedimiento para la produccion de desclaritromicina, asi como prodcutos intermedios.
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US7435805B2 (en) 2003-05-30 2008-10-14 Glaxpsmithkline Istrazivacki O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US7595300B2 (en) 2005-12-13 2009-09-29 Kosan Biosciences Incorporated 7-quinolyl ketolide antibacterial agents
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
GB0616865D0 (en) * 2006-08-25 2007-03-28 Phoenix Chemicals Ltd Process
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
BR112012029586A2 (pt) * 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
KR930702369A (ko) * 1990-10-15 1993-09-08 우에노 아키라 에리쓰로마이신 또는 그의 유도체의 2'위치 수식 화합물

Also Published As

Publication number Publication date
JP2000507573A (ja) 2000-06-20
US5719272A (en) 1998-02-17
EP0891370A1 (de) 1999-01-20
DK0891370T3 (da) 2003-03-24
WO1997036912A1 (en) 1997-10-09
DE69717613D1 (en) 2003-01-16
DE69717613T2 (de) 2003-09-18
JP4116674B2 (ja) 2008-07-09
EP0891370B1 (de) 2002-12-04
PT891370E (pt) 2003-04-30
ES2188896T3 (es) 2003-07-01

Similar Documents

Publication Publication Date Title
DE69717613D1 (en) 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate
CA2279932A1 (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
ATE231851T1 (de) 6-o-alkyl erythronolid-b derivate
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
CA2354774A1 (en) Farnesyl protein transferase inhibitors
FR2745290B1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
BG42675A3 (bg) Метод за получаване на 20-амино-макролидни производни
CZ20011803A3 (cs) Způsob přípravy makrolidových antibiotických látek z nových intermediátů
NO975791D0 (no) Fremgangsmåte for fremstilling av spraybare, kationiske biopolymerer
MD1788G2 (ro) Derivaţi de 9-O-oximă ai Eritromicinei A, compoziţie farmaceutică pe baza lor şi metodă de tratament al bolilor infecţioase
PT1080082E (pt) Intermediarios para a sintese de epotilonas e metodos para a sua preparacao
FR2732023B1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ZA966601B (en) Process for producing erythromycin derivatives.
CA2264513A1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
FR2732684B1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FI953841A7 (fi) Substituoituja kinoliinijohdannaisia, menetelmä niiden valmistamseksi
CA2250736A1 (en) 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin a derivatives
IL117406A0 (en) Novel process for preparing 2,3-dihydro-benzofuranol derivatives
FR2749585B1 (fr) Nouveaux derives aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
PL315479A1 (en) Novel compounds and their salts, method of obtaining them as well as pharmaceutic agent and method of obtaining same
PL327581A1 (en) Method of selectively protecting bacatin derivatives and application thereof in a process of synthesising taxanes
WO1997013776A3 (fr) Nouveaux derives amines de 2', 3' didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux
NZ335325A (en) Erythromycin derivatives, method for preparing them and their use as medicine
DE69935250D1 (de) Oleandomycin-derivate
MY133929A (en) A cost effective method for selective methylation of erythromycin a derivatives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0891370

Country of ref document: EP

REN Ceased due to non-payment of the annual fee